
|Videos|September 9, 2021
Examining new biological treatments in posterior uveitis
Author(s)Sheryl Stevenson, OT Staff Reports
Quan Dong Nguyen, MD, MSc, FARVO, FASRS, highlights his presentation regarding new biological treatments of posterior uveitis.
Advertisement
Quan Dong Nguyen, MD, MSc, FARVO, FASRS, director of the Uveitis and Ocular Inflammation Service, Byers Eye Institute, Stanford University School of Medicine, speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
2
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease
3
Strategic approaches optimize teaching and learning in the clinic
4
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
5












































.png)


